2. Academic Validation
  3. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation

Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation

  • Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8. doi: 10.1016/j.bmcl.2009.01.059.
Kimberly O Cameron 1,  Bruce A Lefker,  Hua Z Ke,  Mei Li,  Michael P Zawistoski,  Christina M Tjoa,  Ann S Wright,  Shari L DeNinno,  Vishwas M Paralkar,  Thomas A Owen,  Li Yu,  David D Thompson
Affiliations

Affiliation

  • 1 Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA. kimberly.o.cameron@pfizer.com
PMID: 19250823 DOI: 10.1016/j.bmcl.2009.01.059
Abstract

Sulfonamides, exemplified by 3a, were identified as highly selective EP(2) agonists. Lead optimization led to the identification of CP-533536, 7f, a potent and selective EP(2) agonist. CP-533536 demonstrated the ability to heal fractures when administered locally as a single dose in rat models of fracture healing.

Figures
Products